📜 Post with us on Reddit
📝 Create a new article
🏭 Create a company page
🇬🇧 - in English
🇫🇷 - en Français (FR)
🇵🇹 - em Português (PT)
🇩🇪 - auf Deutsch (DE)
🇯🇵 - 日本語で (JA)
Sponsored articles

You can edit almost every page by Creating an account and confirming your email.

Nader Rahimi

From EverybodyWiki Bios & Wiki




Nader Rahimi
File:Nader Rahimi Faculty Head Shot.jpg File:Nader Rahimi Faculty Head Shot.jpg
Born (1963-12-22) December 22, 1963 (age 62)
🏡 ResidenceUnited States
🏫 EducationUniversity of Toronto (BS)
Queen's University (PhD)
💼 Occupation

Nader Rahimi (born December 22, 1963) is a Molecular Biologist and is currently an Associate Professor at the Department of Pathology and Laboratory Medicine at Boston University.[1]. Google Scholar Page.

Education

Nader Rahimi received his Bachelor of Science degree in Biochemistry from the University of Toronto in 1991 and received his Ph.D. from Queen's University, Kingston, Canada in 1996.[2] He completed his postdoctoral fellowship at Harvard Medical School in the fields of signal transduction and angiogenesis. [3]

Career

Nader Rahimi has extensively published in the field of signal transduction by receptor tyrosine kinases in particular VEGF receptor tyrosine kinases. His notable works include demonstration of differential function of VEGFR-1 and VEGFR-2 in angiogenesis[4], identification of lysine methylation as a novel mechanism of activation of VEGFR-2[5], establishing protein ubiquitination as a major pathway modulating the angiogenic signaling of VEGFR-2[6][7][8][9]. He is also responsible for the discovery of multiple cell surface receptors including, IGPR-1[10][11][12][13], TMIGD1[14][15], MINAR1[16] and MINAR2[17]. His work on COVID-19 resulted in the discovery of CD209L and CD209 as novel receptors for SARS-COV-2[18][19]

Selected Publications

  • Amraei R, Rahimi N. COVID-19, Renin-Angiotensin System and Endothelial Dysfunction. Cells. 2020 07 09; 9(7). PMID: 32660065.[20]
  • Amraie R, Napoleon MA, Yin W, Berrigan J, Suder E, Zhao G, Olejnik J, Gummuluru S, Muhlberger E, Chitalia V, Rahimi N. CD209L/L-SIGN and CD209/DC-SIGN act as receptors for SARS-CoV-2 and are differentially expressed in lung and kidney epithelial and endothelial cells. bioRxiv. 2020 Jun 23. PMID: 32607506.[21]
  • Vasileva E, Shuvalov O, Petukhov A, Fedorova O, Daks A, Nader R, Barlev N. KMT Set7/9 is a new regulator of Sam68 STAR-protein. Biochem Biophys Res Commun. 2020 May 14; 525(4):1018-1024. PMID: 32178870.[22]
  • Richards S, Walker J, Nakanishi M, Belghasem M, Lyle C, Arinze N, Napoleon MA, Ravid JD, Crossland N, Zhao Q, Rosenberg D, Rahimi N, Chitalia VC. Haploinsufficiency of Casitas B-Lineage Lymphoma Augments the Progression of Colon Cancer in the Background of Adenomatous Polyposis Coli Inactivation. Am J Pathol. 2020 03; 190(3):602-613. PMID: 32113662.[23]
  • Lyle C, Richards S, Yasuda K, Napoleon MA, Walker J, Arinze N, Belghasem M, Vellard I, Yin W, Ravid JD, Zavaro E, Amraei R, Francis J, Phatak U, Rifkin IR, Rahimi N, Chitalia VC. c-Cbl targets PD-1 in immune cells for proteasomal degradation and modulates colorectal tumor growth. Sci Rep. 2019 12 27; 9(1):20257. PMID: 31882749.[24]

References

  1. ↑ https://www.bumc.bu.edu/busm-pathology/people_main/nader-rahimi-phd/
  2. ↑ https://www.bumc.bu.edu/busm/profile/nader-rahimi/
  3. ↑ https://www.bumc.bu.edu/ophthalmology/research-programs/nader-rahimi-phd/
  4. ↑ Rahimi, N.; Dayanir, V.; Lashkari, K. (2000). "Receptor chimeras indicate that the vascular endothelial growth factor receptor-1 (VEGFR-1) modulates mitogenic activity of VEGFR-2 in endothelial cells". The Journal of Biological Chemistry. 275 (22): 16986–92. doi:10.1074/jbc.M000528200. PMID 10747927. Unknown parameter |s2cid= ignored (help)
  5. ↑ Hartsough, E. J.; Meyer, R. D.; Chitalia, V.; Jiang, Y.; Marquez, V. E.; Zhdanova, I. V.; Weinberg, J.; Costello, C. E.; Rahimi, N. (2013). "Lysine methylation promotes VEGFR-2 activation and angiogenesis". Science Signaling. 6 (304): ra104. doi:10.1126/scisignal.2004289. PMC 4108444. PMID 24300896.
  6. ↑ https://www.researchgate.net/publication/38085465_A_role_for_protein_ubiquitination_in_BEGFR-2_signaling_and_angiogenesis
  7. ↑ Meyer, R. D.; Srinivasan, S.; Singh, A. J.; Mahoney, J. E.; Gharahassanlou, K. R.; Rahimi, N. (2011). "PEST Motif Serine and Tyrosine Phosphorylation Controls Vascular Endothelial Growth Factor Receptor 2 Stability and Downregulation". Molecular and Cellular Biology. 31 (10): 2010–2025. doi:10.1128/MCB.01006-10. PMC 3133358. PMID 21402774.
  8. ↑ https://www.pnas.org/content/104/13/5413
  9. ↑ Meyer, R. D.; Husain, D.; Rahimi, N. (2011). "C-CBL inhibits angiogenesis and tumor growth by suppressing activation of PLCγ1". Oncogene. 30 (19): 2198–2206. doi:10.1038/onc.2010.597. PMC 3969724. PMID 21242968.
  10. ↑ https://www.jbc.org/content/early/2019/07/24/jbc.RA119.008548.full.pdf[permanent dead link]
  11. ↑ Woolf, N.; Pearson, B. E.; Bondzie, P. A.; Meyer, R. D.; Lavaei, M.; Belkina, A. C.; Chitalia, V.; Rahimi, N. (2017). "Targeting tumor multicellular aggregation through IGPR-1 inhibits colon cancer growth and improves chemotherapy". Oncogenesis. 6 (9): e378–. doi:10.1038/oncsis.2017.77. PMC 5623903. PMID 28920928.
  12. ↑ Wang, Y. H.; Meyer, R. D.; Bondzie, P. A.; Jiang, Y.; Rahimi, I.; Rezazadeh, K.; Mehta, M.; Laver, N. M.; Costello, C. E.; Rahimi, N. (2016). "IGPR-1 is Required for Endothelial Cell-Cell Adhesion and Barrier Function". Journal of Molecular Biology. 428 (24 Pt B): 5019–5033. doi:10.1016/j.jmb.2016.11.003. PMC 5138093. PMID 27838321.
  13. ↑ Rahimi, N.; Rezazadeh, K.; Mahoney, J. E.; Hartsough, E.; Meyer, R. D. (2012). "Identification of IGPR-1 as a novel adhesion molecule involved in angiogenesis". Molecular Biology of the Cell. 23 (9): 1646–1656. doi:10.1091/mbc.E11-11-0934. PMC 3338432. PMID 22419821.
  14. ↑ Meyer, R. D.; Zou, X.; Ali, M.; Ersoy, E.; Bondzie, P. A.; Lavaei, M.; Alexandrov, I.; Henderson, J.; Rahimi, N. (2017). "TMIGD1 acts as a tumor suppressor through regulation of p21Cip1/P27Kip1 in renal cancer". Oncotarget. 9 (11): 9672–9684. doi:10.18632/oncotarget.23822. PMC 5839393. PMID 29515762.
  15. ↑ Arafa, E.; Bondzie, P. A.; Rezazadeh, K.; Meyer, R. D.; Hartsough, E.; Henderson, J. M.; Schwartz, J. H.; Chitalia, V.; Rahimi, N. (2015). "TMIGD1 is a novel adhesion molecule that protects epithelial cells from oxidative cell injury". The American Journal of Pathology. 185 (10): 2757–67. doi:10.1016/j.ajpath.2015.06.006. PMC 4607757. PMID 26342724.
  16. ↑ Ho, R. X.; Meyer, R. D.; Chandler, K. B.; Ersoy, E.; Park, M.; Bondzie, P. A.; Rahimi, N.; Xu, H.; Costello, C. E.; Rahimi, N. (2018). "MINAR1 is a Notch2-binding protein that inhibits angiogenesis and breast cancer growth". Journal of Molecular Cell Biology. 10 (3): 195–204. doi:10.1093/jmcb/mjy002. PMC 6025234. PMID 29329397.
  17. ↑ https://academic.oup.com/braincomms/article/2/1/fcaa047/5823289
  18. ↑ Amraie, Razie; Napoleon, Marc A.; Yin, Wenqing; Berrigan, Jacob; Suder, Ellen; Zhao, Grace; Olejnik, Judith; Gummuluru, Suryaram; Muhlberger, Elke; Chitalia, Vipul; Rahimi, Nader (2020). "CD209L/L-SIGN and CD209/DC-SIGN act as receptors for SARS-CoV-2 and are differentially expressed in lung and kidney epithelial and endothelial cells". bioRxiv : The Preprint Server for Biology. doi:10.1101/2020.06.22.165803. PMC 7325172 Check |pmc= value (help). PMID 32607506 Check |pmid= value (help).
  19. ↑ https://www.mdpi.com/2073-4409/9/7/1652
  20. ↑ Amraei R, Rahimi N. COVID-19, Renin-Angiotensin System and Endothelial Dysfunction. Cells. 2020 07 09; 9(7). PMID: 32660065. https://pubmed.ncbi.nlm.nih.gov/32660065/
  21. ↑ Amraie R, Napoleon MA, Yin W, Berrigan J, Suder E, Zhao G, Olejnik J, Gummuluru S, Muhlberger E, Chitalia V, Rahimi N. CD209L/L-SIGN and CD209/DC-SIGN act as receptors for SARS-CoV-2 and are differentially expressed in lung and kidney epithelial and endothelial cells. bioRxiv. 2020 Jun 23. PMID: 32607506. https://pubmed.ncbi.nlm.nih.gov/32607506/
  22. ↑ Vasileva E, Shuvalov O, Petukhov A, Fedorova O, Daks A, Nader R, Barlev N. KMT Set7/9 is a new regulator of Sam68 STAR-protein. Biochem Biophys Res Commun. 2020 May 14; 525(4):1018-1024. PMID: 32178870. https://pubmed.ncbi.nlm.nih.gov/32178870/
  23. ↑ Richards S, Walker J, Nakanishi M, Belghasem M, Lyle C, Arinze N, Napoleon MA, Ravid JD, Crossland N, Zhao Q, Rosenberg D, Rahimi N, Chitalia VC. Haploinsufficiency of Casitas B-Lineage Lymphoma Augments the Progression of Colon Cancer in the Background of Adenomatous Polyposis Coli Inactivation. Am J Pathol. 2020 03; 190(3):602-613. PMID: 32113662. https://pubmed.ncbi.nlm.nih.gov/32113662/
  24. ↑ Lyle C, Richards S, Yasuda K, Napoleon MA, Walker J, Arinze N, Belghasem M, Vellard I, Yin W, Ravid JD, Zavaro E, Amraei R, Francis J, Phatak U, Rifkin IR, Rahimi N, Chitalia VC. c-Cbl targets PD-1 in immune cells for proteasomal degradation and modulates colorectal tumor growth. Sci Rep. 2019 12 27; 9(1):20257. PMID: 31882749. https://pubmed.ncbi.nlm.nih.gov/31882749/


This article "Nader Rahimi" is from Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:Nader Rahimi. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.

Page kept on Wikipedia This page exists already on Wikipedia.

Retrieved from "https://en.everybodywiki.com/index.php?title=Nader_Rahimi&oldid=6455383"
License CC BY-SA 3.0
Powered by MediaWiki